PPARs as Potential Inducers of Antineoplastic Effects in CNS Tumors
Author Information
Author(s): Lars Tatenhorst, Eric Hahnen, Michael T. Heneka
Primary Institution: University of Bonn and University of Cologne
Hypothesis
Can PPAR agonists induce antineoplastic effects in CNS tumors?
Conclusion
PPAR agonists, especially thiazolidinediones, show promise as new therapeutic approaches for treating CNS tumors due to their antiproliferative and anti-invasive effects.
Supporting Evidence
- PPAR agonists have shown to inhibit growth and induce apoptosis in glioma cells.
- Activation of PPARĪ³ is linked to reduced cell adhesion and migration in gliomas.
- Thiazolidinediones are FDA-approved for diabetes and may have antineoplastic properties.
Takeaway
Scientists are studying how certain drugs can help fight brain tumors by affecting specific proteins in our cells. These drugs might help stop the tumors from growing.
Methodology
The review analyzed various studies on PPARs and their effects on CNS tumors, focusing on both natural and synthetic ligands.
Limitations
Most studies were conducted on long-term cultured cell lines, which may not accurately represent natural conditions.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website